

**SO-CALLED  
FIBROHISTIOCYTIC TUMOURS:  
AN OVERVIEW FOCUSSED ON  
LESIONS IN WHICH BIOLOGIC  
POTENTIAL MAY BE  
MISINTERPRETED**

**Christopher D.M. Fletcher, M.D., FRCPath  
Brigham and Women's Hospital  
and Harvard Medical School  
Boston, MA**

**SO-CALLED  
FIBROHISTIOCYTIC TUMOURS  
COMMONEST MISINTERPRETATIONS  
BENIGN LESIONS  
DIAGNOSED AS MALIGNANT**

**Cellular fibrous histiocyoma  
Aneurysmal fibrous histiocyoma  
Epithelioid fibrous histiocyoma  
Atypical fibrous histiocyoma  
Deep benign fibrous histiocyoma  
(Diffuse-type giant cell tumour)  
Atypical fibroxanthoma**

**SO-CALLED  
FIBROHISTICYTIC TUMOURS  
MALIGNANT LESIONS  
DIAGNOSED AS BENIGN**

**Low-grade myxofibrosarcoma**

**Much less often a problem**

**SO-CALLED  
FIBROHISTIOCYTIC TUMOURS  
LESIONS IN WHICH BIOLOGIC  
POTENTIAL IS DIFFICULT TO PREDICT**

**Plexiform fibrohistiocytic tumour**

**Angiomatoid 'MFH'**

**Most pursue a benign clinical course  
but approx. 2% (?) metastasise**

# **CELLULAR BENIGN FIBROUS HISTIOCYTOMA**

## **CLINICAL FEATURES**

**Wide age range**

**Peak incidence 15-45 years**

**Limbs > head & neck > elsewhere**

**Poorly marginated nodule**

**Most < 3 cm**

**May grow rapidly**

**Local recurrence in 15-20%**

**Exceptionally metastasise**



# **CELLULAR BENIGN FIBROUS HISTIOCYTOMA**

## **DISTINCTIVE HISTOLOGIC FEATURES**

**Larger, more cellular**

**Often extends into subcutis**

**Often fascicular and 'myoid'**


**Relative paucity of giant or foamy cells**


**Frequent mitoses**


**Occasional central necrosis**


























**SMA**



# **CELLULAR BENIGN FIBROUS HISTIOCYTOMA**

## **CLINICAL RELEVANCE**

**Ordinary FH**

**Approx. 2% recur**

**Non-destructive**

**Cellular FH**

**15-20% recur**

**Non-destructive**


**Very rare metastasis**


**DFSP**

**30% or more recur**

**Locally infiltrative**

**No metastasis unless FS-DFSP**





## **NOTABLE FEATURES OF METASTASISING CUTANEOUS FH**

- **Frequently preceded by repeated local recurrence**
- **Predilection to spread to lymph nodes and lung**
- **Metastases may be delayed for many years; lung lesions may be indolent**
- **Metastases usually closely resemble the primary lesion**

# **CELLULAR BENIGN FIBROUS HISTIOCYTOMA DIFFERENTIAL DIAGNOSIS**

## **Dermatofibrosarcoma protuberans**

- **more basophilic**
- **less polymorphic**
- **CD34 positive**

## **Cutaneous “leiomyosarcoma”**

- **cigar-shaped nuclei**
- **infiltrative dermal growth**
- **desmin positive (in skin)**

**ANEURYSMAL BENIGN  
FIBROUS HISTIOCYTOMA  
CLINICAL FEATURES**

**Approx. 5% of cutaneous FH**

**Adults; peak 20-40 years**

**Females slightly > males**

**Lower limb ++ > trunk > elsewhere**


**Red / brown nodule up to 2-3 cm**

**Occasional rapid growth / pain**


**15-20% local recurrence**


**Rare metastasis**




















**ANEURYSMAL BENIGN  
FIBROUS HISTIOCYTOMA  
DIFFERENTIAL DIAGNOSIS**

**Angiomatoid “MFH”  
Kaposi’s sarcoma  
(Spindle cell haemangioma)  
(Angiosarcoma)**

**CELLULAR / ANEURYSMAL VARIANTS  
OF BENIGN FIBROUS HISTIOCYTOMA  
WORRISOME FEATURES**

**Frequently large size  
Cellularity  
Relatively high mitotic rate  
Focal necrosis in 10-15%**

# **EPITHELIOID BENIGN FIBROUS HISTIOCYTOMA**

**Less than 2% of cutaneous FH**  
**Clinically similar to ordinary FH**  
**BUT**


**Usually polypoid / exophytic**  
**Frequent collarette**


**At least 50% of cells epithelioid**  
**Polygonal / eosinophilic / binucleate cells**  
**Often prominent vessels**


**Local recurrence uncommon**





















**EMA**





**EPITHELIOID BENIGN  
FIBROUS HISTIOCYTOMA  
DIFFERENTIAL DIAGNOSIS**

**Spitz naevus**

**Juvenile xanthogranuloma**

**Malignant melanoma**

**Epithelioid sarcoma**

**Epithelioid vascular tumour**

**ATYPICAL (PSEUDOSARCOMATOUS)  
FIBROUS HISTIOCYTOMA  
CLINICAL FEATURES**

**Less than 2% of cutaneous FH**

**Adults; peak 20-40 years**

**Equal sex incidence**

**Limbs ++ > Elsewhere**

**Nodular / polypoid**

**10-15% local recurrence**

**Rare metastasis**

**(a.k.a. ‘dermatofibroma with monster cells’)**

**ATYPICAL ('PSEUDOSARCOMATOUS')**  
**FIBROUS HISTIOCYTOMA**  
**MORPHOLOGIC FEATURES**


**Similar to usual FH**


**EXCEPT**


**Scattered large bizarre pleomorphic cells**  
**(often multinucleate / foamy)**


**30% have atypical mitoses**


**10% have necrosis**

























# **ATYPICAL FIBROUS HISTIOCYTOMA**

## **DIFFERENTIAL DIAGNOSIS**

**Atypical fibroxanthoma**  
**Pleomorphic sarcoma (“MFH”)**  
**(Sarcomatoid SCC)**  
**(Metastasis)**

## **ATYPICAL FIBROXANTHOMA**

**‘...histologically bizarre tumor usually found in sun-damaged skin of elderly persons... had been initially misdiagnosed as a variety of sarcomas or carcinomas...benign behavior of these lesions is documented. It is suggested that AFX represents a reactive or reparative process in previously damaged dermis.’**

**Kempson & McGavran**

**Cancer 1964; 17:1463-1471**

## **ATYPICAL FIBROXANTHOMA**

**‘...one may speculate that it represents part of a spectrum of reactive processes.... The series of 140 cases....appears to further establish AFX as a mesenchymal proliferation of the dermis characterized by a bizarre and pleomorphic sarcoma-like histologic appearance but but with a disposition to benign biologic behaviour.’**

**Fretzin & Helwig**

**Cancer 1973; 31:1541-52**

## **ATYPICAL FIBROXANTHOMA**

**‘It is histologically indistinguishable from pleomorphic forms of malignant fibrous histiocyoma. From a conceptual point of view, we regard it as a superficial form of that tumor which, by virtue of its superficial location, almost invariably pursues a benign course.’**

**Enzinger & Weiss, 1<sup>st</sup> Ed<sup>n</sup>, 1983**



# **‘ATYPICAL FIBROXANTHOMA’ WITH METASTASIS**

**‘Factors that portend aggressive behavior and metastasis are vascular invasion, recurrence, deep tissue invasion, tumor necrosis.....’**

**Helwig & May**

**Cancer 1986; 57:368-376**

# **ATYPICAL FIBROXANTHOMA PROBLEMS**

- **Diagnostic criteria**
- **Cases in the pre-immuno era**
- **Shave biopsies**
- **Rare keratin-negative cases of spindle cell SCC with ulceration**

# **ATYPICAL FIBROXANTHOMA**

## **CLINICAL FEATURES**

**Mainly elderly patients**

**Males > females**

**Head and neck++ / limbs rare**

**Rapidly enlarging exophytic**

**Sometimes multiple / asynchronous**

**Recurrence infrequent**

**No metastasis if carefully diagnosed**



# **ATYPICAL FIBROXANTHOMA**

## **MORPHOLOGIC FEATURES**

**Arise in actinically damaged skin**

**Usually very cellular / mitotic**

**Variably pleomorphic / bizarre**

**Often ulcerated**


**Frequent collarette**


**Usually confined to dermis**


**Smooth deep margin**

**No epidermal / junctional component**


**Keratin / S-100 protein / desmin negative**
























A histological slide showing a transition from stratified squamous epithelium (top left) to a dense cellular area (bottom right). The epithelium is stained brown, while the underlying cells are stained blue. The text 'PAN-K' is overlaid in a white box in the upper right corner.

**PAN-K**



**S-100**

# **ATYPICAL FIBROXANTHOMA**

## **IMPORTANT CRITERIA**

**Origin in sun-damaged skin**

**No epidermal / junctional origin**

**No subcutaneous (or deeper) invasion**

**No necrosis (except surface)**

**No vascular or perineural invasion**

**Relevant negative immuno**



# **ATYPICAL FIBROXANTHOMA**

## **CONCEPTUAL QUESTIONS**

**What are they ?**

**What is the role of U-V irradiation ?**

**Do they occur in young patients ?**

**Do they ever metastasise ?**

**Are they related to 'MFH' ?**

**MYXOFIBROSARCOMA  
(FORMERLY MYXOID 'MFH')**  
**CLINICAL FEATURES**

**Adults; peak 50-70 years**

**Equal sex incidence**

**Lower limb > upper limb > trunk**


**Retroperit and head/neck rare**


**60-70% Subcutaneous / deep dermal**


**Some tendency to nodal metastasis**

**Survival depends on grade**



























# MYXOFIBROSARCOMA

## METASTASES / TUMOUR-RELATED DEATHS

	Superficial	Deep
Low	0%	0%
Intermed	20%	30%
High	30%	35%

Local recurrence(s) may advance in grade

# **PLEXIFORM FIBROHISTIOCYTIC TUMOUR**

## **CLINICAL FEATURES**

**Commonest 0-30 years**

**Wide age range**

**F > M 3:1**

**65% upper limb**

**Slowly growing dermal / subcut mass**

**20-30% local recurrence**

**Nodal / systemic metastasis ~ 2% (? more)**

# **PLEXIFORM FIBROHISTIOCYTIC TUMOUR**

## **PATHOLOGIC FEATURES**

**Most < 3 cm**

**Poorly demarcated**


**Centred on dermal / subcut junction**

**Variable proportions of:**


- spindle cell fascicles**
- aggregates of histiocytoid cells**


**Osteoclastic giant cells common**


**Vascular invasion ~ 30%**




















**CD68**




**SMA**









**PLEXIFORM  
FIBROHISTIOCYTIC TUMOUR  
DIFFERENTIAL DIAGNOSIS**

**Ordinary fibrous histiocyoma**

**Fibromatosis**

**Giant cell tumour of soft tissue**

**(Giant cell tumour of tendon sheath)**

**(Granulomatous process)**

# **SO-CALLED ANGIOMATOID 'MFH'**

## **CLINICAL FEATURES**

**Children / adolescents / young adults**

**Equal sex incidence**

**Limbs > trunk**

**Most often subcutaneous**

**Slowly growing, usually < 5 cm**

**Often mistaken for haematoma**

**Systemic features in < 5%**

**- fever, weight loss, anaemia, ESR ↑**

**Local recurrence approx. 10%**

**Metastasis < 2%**



# **SO-CALLED ANGIOMATOID 'MFH'**

## **PATHOLOGIC FEATURES**

**Multinodular, haemorrhagic  
Nodules / sheets of  
eosinophilic ovoid to spindle cells**

**Pleomorphism infrequent**

**Lymphoplasmacytic infiltrate**

**Dense collagenous stroma**

**Haemosiderin deposition**


**Some variability**


**Desmin / EMA positive in 40-50%**


**CD68 and CD99 often positive (? significance)**

**Specific fusion gene(s)**


**Usually *EWSR1-CREB1* ; less often *EWSR1-ATF1***





























**DES**





**EMA**





**SO-CALLED ANGIOMATOID 'MFH'**  
**DIFFERENTIAL DIAGNOSIS**

**Aneurysmal benign FH**  
**Diffuse-type giant cell tumour**  
**Organising haematoma**  
**Dendritic cell neoplasm (?)**

# **SO-CALLED ANGIOMATOID 'MFH'**

## **LINE OF DIFFERENTIATION**

**Currently unknown**

**Numerous hypotheses over the years**

**? Myoid / perivascular differentiation**

**? Fibroblastic reticulum cell (or similar)**

# **SO-CALLED FIBROHISTIOCYTIC TUMOURS HOW TO AVOID MISINTERPRETATION ?**

- **Think about clinical context**
- **Develop understanding of natural history**
- **Avoid ‘knee-jerk’ response to cytologic atypia or mitoses**
- **Thoughtful use of immunostains**
- **Acknowledge uncertainty and, if required, seek consultation**